PUBLISHER: KuicK Research | PRODUCT CODE: 1812619
PUBLISHER: KuicK Research | PRODUCT CODE: 1812619
Global Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030
Global Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030 Report Findings & Highlights:
- Research Methodology
- Global Breast Cancer Antibody Drug Conjugates Market Opportunity: > US$ 20 Billion By 2030
- Global & Regional Market Size Insight (Yearly & Quarterly): 2020 Till H1'2025
- Approved Breast Cancer Antibody Drug Conjugates Sales Insight : 2020 Till 2025
- Global Cancer Antibody Drug Conjugates Market Forecast: 2026 Till 2030
- Approved Breast Cancer Antibody Drug Conjugates Patent, Dosage and Price Analysis
- Breast Cancer Antibody Drug Conjugates In Clinical Trials: > 100 Drugs
- Breast Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase
- Cancer Antibody Drug Conjugates Development Platforms By Company
Need For Antibody Drug Conjugates In Breast Cancer Treatment & Why This Report
Antibody drug conjugates (ADCs) are rapidly becoming an essential innovation in the battle against breast cancer, specifically in fulfilling the unmet needs of patients with HER2-positive and HER2-low tumors. These drugs leverage the precision targeting of monoclonal antibodies along with the potent cytotoxic effects of chemotherapeutic drugs to achieve more localized destruction of the tumor while avoiding systemic toxicity. The global market has identified this potential, with breast cancer ADCs sales exceeding US$ 7 Billion in 2024, and further expected to triple by 2030.
The purpose of this report is to provide an incisive, timely, and strategic insight into the developing landscape of breast cancer ADCs. As the space evolves from nascent research into broad clinical acceptance, stakeholders, ranging from pharmaceutical developers to investors, need current intelligence on clinical developments, trial design, platform technologies, and commercialization avenues. By boiling down sophisticated global data by geography, subtype, and trial phase, this report arms decision-makers with the insights needed to navigate and shape the direction of breast cancer treatment.
Clinical Trials Insight Included In Report
The report contains extensive analysis of ADC candidates for breast cancer, from early Phase 1 to late stage Phase 3 trials, including extensive data on already approved breast cancer ADCs These trials span across key geographies like the US, Europe, China, and Australia. Clinical data not only target the classic HER2-positive patients but also the emerging HER2-low patient population, a new area in breast cancer precision medicine. Report includes insight on more than 120 breast cancer antiboduies drug conjugates.
The most crucial variables examined are therapeutic strategy (monotherapy versus combination regimens), sponsorship of trials (academic centers versus industry), and molecular targets other than HER2, i.e., TROP2 and B7-H4. The key contenders in the late-stage pipeline are Enhertu, Trodelvy, Datroway, and new entrants such as DP303c, Izalontamab brengitecan, and JSKN003. Combination studies, such as sacituzumab govitecan with pembrolizumab or trastuzumab, are also investigated, providing solutions to mechanisms of resistance. Companion diagnostics, including Roche's TROP2 assay based on AI, are also included in trial designs to enable biomarker-based patient selection. Combined, all these insights chart the most productive and successful clinical activities globally.
Top Companies Working On R&D of Breast Cancer Antibody Drug Conjugates
A number of pharma titans and cutting-edge biotech players are defining the breast cancer ADC market. Daiichi Sankyo and AstraZeneca dominate with Enhertu, the category leader in global sales. Roche and Genentech remain active through Kadcyla and diagnostics. Seagen, having just been acquired by Pfizer, is adding pipeline depth, while ADC Therapeutics and Mersana Therapeutics are gaining traction with differentiated platforms.
Emerging companies such as RemeGen and Zydus Cadila are broadening the geographic reach, especially in Asia. Each company is developing new payloads, linkers, and antibody formats to decrease toxicity and enhance clinical efficacy. These are manifestations not only of innovation, but of intense competition that's driving global development and access.
Technology Platforms, Collaborations & Agreements
Technology platforms are the biggest differentiator in breast cancer ADCs. Companies are optimizing conjugation methods, linker chemistry, and payload delivery systems. For instance, bispecific ADCs (BsADCs), targeting two antigens at the same time, are being introduced as a next-generation answer for tumor heterogeneity. Part of the success of Enhertu lies in its high drug-to-antibody ratio and stable linker technology.
Collaborations are also driving expansion. Pfizer's acquisition of Seagen added propriety ADC platforms to its fold. Academic research institution-industry collaborations, like in the form of clinical trial partnerships,are speeding up candidate development. Licensing deals and local manufacturing support through CDMOs are also making access wider, particularly across emerging markets like India, China, and Latin America.
Report Indicating Future Direction Of Breast Cancer Antibody Drug Conjugates
This report predicts that breast cancer will continue to be the predominant indication for ADC innovation and commercialization. With additional candidates making their way into late-stage trials, and combination regimens demonstrating early efficacy, the future is directed toward more personalized and targeted therapy. Emerging innovations to watch are bispecific ADCs, increased biomarker testing, use in neoadjuvant/adjuvant treatment, and use in early-stage disease.
Regulatory momentum, investment capital, and scientific advancements are all coming together to pave the way for ADCs to be a cornerstone in the treatment of breast cancer. With an active pipeline, mounting international approvals, and growing indications, breast cancer ADCs can change the face of oncology care.
Table of Contents
1. Introduction To Breast Cancer Antibody Drug Conjugates
2. Antibody Drug Conjugates As Breast Cancer Targeted Therapy
- 2.1 Mechanism Of Antibody Drug Conjugates
- 2.2 Applications & Advantages In Breast Cancer
- 2.3 Comparison With Traditional Therapies
- 2.4 Breast Cancer Antibody Drug Conjugates Combination Therapies
3. Generations Of Breast Cancer Antibody Drug Conjugates
- 3.1 Antibody Drug Conjugates - Evolution
- 3.2 Next Generation Antibody Drug Conjugates Prospects
4. Commercially Approved Breast Cancer Antibody Drug Conjugates By Brand Name, Company & Indication
5. Global Breast Cancer Antibody Drug Conjugates Market Outlook
- 5.1 Current Market Scenario
- 5.2 Global Breast Cancer Antibody Drug Conjugates Market Trends & Development
- 5.3 Future Growth Avenues
6. Global Cancer Antibody Drug Conjugates Research & Market Trends By Region
- 6.1 US
- 6.2 China
- 6.3 Europe
- 6.4 South Korea
- 6.5 Australia
- 6.6 Canada
- 6.7 Japan
- 6.8 UK
- 6.9 India
- 6.10 Latin America
7. Approved Breast Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis
This Chapter Gives Insight On 7 Approved Breast Cancer Antibody Drug Conjugates
- 7.1 Kadcyla
- 7.1.1 Overview, Availability & Patent Insight
- 7.1.2 P ricing & Dosage Insight
.
- 7.7 Aidixi
- 7.7.1 Overview & Availability Insight
8. Approved Breast Cancer Antibody Drug Conjugates Sales Insights
- 8.1 Kadcyla
- 8.2 Enhertu
- 8.3 Trodelvy
- 8.4 Datroway
9. Global Cancer Antibody Drug Conjugates Clinical Trials Overview
- 9.1 By Phase
- 9.2 By Indication
- 9.3 By Company
- 9.4 By Country
10. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
- 10.1 Research
- 10.2 Preclinical
- 10.3 Phase I
- 10.4 Phase I/II
- 10.5 Phase II
- 10.6 Phase II/III
- 10.7 Phase III
- 10.8 Preregistration
- 10.9 Registered
11. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
12. Cancer Antibody Drug Conjugates Development Platforms By Company
13. Global Cancer Antibody Drug Conjugates Market Overview
- 13.1 Key Market Growth Drivers
- 13.2 Challenges For Market Growth
14. Competitive Landscape
- 14.1 ADC Therapeutics
- 14.2 AstraZeneca
- 14.3 Biocytogen
- 14.4 Biokin
- 14.5 Bristol Myers Squibb
- 14.6 Daiichi Sankyo
- 14.7 Duality Biologics
- 14.8 Eli Lilly
- 14.9 Gilead
- 14.10 Immunogen
- 14.11 Innovent Biologics
- 14.12 LigaChem Biosciences
- 14.13 Merck
- 14.14 Pfizer
- 14.15 Roche
List of Figures
- Figure 2-1: Antibody Drug Conjugates - General Working Mechanism
- Figure 2-2: Advantages Of Antibody Drug Conjugates
- Figure 2-3: Antibody Drug Conjugate Combinations In Studies
- Figure 3-1: Cancer Antibody Drug Conjugates - Opportunities For Next Generation Development
- Figure 5-1: Global - Breast Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2025
- Figure 5-2: Global - Breast Cancer Antibody Drug Conjugate Sales By Drugs (US$ Million), H1'2025
- Figure 5-3: Global - Cancer Antibody Drug Conjugate Market Share By Drugs (%), H1'2025
- Figure 5-4: Global - Breast Cancer Antibody Drug Conjugate Market (US$ Million), Q1 & Q2'2025
- Figure 5-5: Global - Breast Cancer Antibody Drug Conjugate Sales By Drugs (US$ Million), 2024
- Figure 5-6: Global - Breast Cancer Antibody Drug Conjugate Market Share By Drugs (%), 2024
- Figure 5-7: Global - Breast Cancer Antibody Drug Conjugate Market (US$ Million), Q1 -Q4'2024
- Figure 5-8: Global - Breast Cancer Antibody Drug Conjugate Market By Drugs (US$ Million), 2023
- Figure 5-9: Global - Cancer Antibody Drug Conjugate Market Share By Drugs (%), 2023
- Figure 5-10: D926QC00001 Phase 3 (NCT06112379) Study - Initiation & Completion Year
- Figure 5-11: TQB2102-III-01 Phase 3 (NCT06561607) Study - Initiation & Completion Year
- Figure 5-12: IZABRIGHT-Breast01 Phase 2/3 (NCT06926868) Study - Initiation & Completion Year
- Figure 5-13: STARt-002 Phase 1/2 (NCT06827613) Study - Initiation & Completion Year
- Figure 5-14: Global - Breast Cancer Antibody Drug Conjugate Market Forecast (US$ Billion), 2026 - 2030
- Figure 6-1: India - Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), September'2025
- Figure 7-1: US - Kadcyla FDA Approval Year By Indication
- Figure 7-2: Kadcyla - Approval Year By Region
- Figure 7-3: US - Kadcyla FDA Approval & Patent Expiration Year
- Figure 7-4: Kadcyla - Cost of Supply In US & Europe (US$), September'2025
- Figure 7-5: Kadcyla - Recommended Dose after 1st & 2nd Dose Reduction (mg/kg)
- Figure 7-6: Enhertu - Approval Year By Region
- Figure 7-7: US - Polivy FDA Approval Year by Indication
- Figure 7-8: Enhertu - FDA Orphan Drug Designation & Exclusivity Expiration Year
- Figure 7-9: Enhertu - Cost of 100 mg Supply In US & Europe (US$), September'2025
- Figure 7-10: US - Trodelvy FDA Approval by Indication
- Figure 7-11: Trodelvy - Approval Year By Region
- Figure 7-12: Trodelvy - Patent Expiration By Region
- Figure 7-13: Trodelvy - Cost of Supply In US & Europe (US$), September'2025
- Figure 7-14: Ujvira - Cost of 100 mg & 160 mg Supply in India (US$), September'2025
- Figure 7-15: Datroway - Cost of 100 mg Supply In US & Europe (US$), September'2025
- Figure 8-1: Kadcyla - Global Sales (US$ Million), 2020-2025
- Figure 8-2: Kadcyla - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
- Figure 8-3: Kadcyla - Global Sales By Region (%), H1'2025
- Figure 8-4: Kadcyla - Global Quarterly Sales (US$ Million), Q1-Q4'2024
- Figure 8-5: Kadcyla - Global Sales By Region (US$ Million), 2024
- Figure 8-6: Kadcyla - Global Sales By Region (%), 2024
- Figure 8-7: Kadcyla - US Annual Sales (US$ Million), 2020-2025
- Figure 8-8: Kadcyla - US Quarterly Sales (US$ Million), Q1 & Q2'2025
- Figure 8-9: Kadcyla - US Quarterly Sales (US$ Million), Q1-Q4'2024
- Figure 8-10: Kadcyla - Europe Annual Sales (US$ Million), 2020-2025
- Figure 8-11: Kadcyla - Europe Quarterly Sales (US$ Million), Q1'2025
- Figure 8-12: Kadcyla - Europe Quarterly Sales (US$ Million), Q1-Q4'2024
- Figure 8-13: Kadcyla - Japan Annual Sales (US$ Million), 2020-2025
- Figure 8-14: Kadcyla - Japan Quarterly Sales (US$ Million), Q1 & Q2'2025
- Figure 8-15: Kadcyla - Japan Quarterly Sales (US$ Million), Q1-Q4'2024
- Figure 8-16: Kadcyla - ROW Annual Sales (US$ Million), 2020-2025
- Figure 8-17: Kadcyla - ROW Quarterly Sales (US$ Million), Q1 & Q2'2025
- Figure 8-18: Kadcyla - ROW Quarterly Sales (US$ Million), Q1-Q4'2024
- Figure 8-19: Enhertu - Global Annual Sales (US$ Million), 2020-2025
- Figure 8-20: Enhertu - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
- Figure 8-21: Enhertu - Global Quarterly Sales (US$ Million), Q1-Q4'2024
- Figure 8-22: Trodelvy - Global Annual Sales (US$ Million), 2020-2025
- Figure 8-23: Trodelvy - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
- Figure 8-24: Trodelvy - Annual Sales By Region (US$ Million), 2025
- Figure 8-25: Trodelvy - Annual Sales By Region (%), 2025
- Figure 8-26: Trodelvy - Global Quarterly Sales (US$ Million), Q1-Q4'2024
- Figure 8-27: Trodelvy - Annual Sales By Region (US$ Million), 2024
- Figure 8-28: Trodelvy - Annual Sales By Region (%), 2024
- Figure 8-29: Trodelvy - US Annual Sales (US$ Million), 2020-2025
- Figure 8-30: Trodelvy - US Quarterly Sales (US$ Million), Q1 & Q2'2025
- Figure 8-31: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4'2024
- Figure 8-32: Trodelvy - Europe Annual Sales (US$ Million), 2020-2025
- Figure 8-33: Trodelvy - Europe Quarterly Sales (US$ Million), Q1 & Q2'2025
- Figure 8-34: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4'2024
- Figure 8-35: Trodelvy - ROW Annual Sales (US$ Million), 2022-2025
- Figure 8-36: Trodelvy - ROW Quarterly Sales (US$ Million), Q1 & Q2'2025
- Figure 8-37: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4'2024
- Figure 8-38: Datroway - Global Annual Sales (US$ Million), 2025
- Figure 8-39: Datroway - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
- Figure 9-1: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2030
- Figure 9-2: Global- Cancer Antibody Drug Conjugate In Clinical Trials By Indication, 2025 Till 2030
- Figure 9-3: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Company, 2025 Till 2030
- Figure 9-4: Global - Cancer Antibody Drug Conjugate In Clinical Pipeline By Country, 2025 Till 2030
- Figure 12-1: Proprietary ADC Technology - Seagen
- Figure 12-2: ALE.P02 & ALE.P03 - Alentis Therapeutics
- Figure 12-3: TRAAC - Tallac Therapeutics
- Figure 12-4: ATAC - Heidelberg Pharma
- Figure 12-5: Tub-tag(R) & P5 - Tubulis
List of Tables
- Table 2-1: Comparison Between Antibody Drug Conjugates & Traditional Cancer Therapies
- Table 2-2: Breast Cancer - Ongoing Antibody Drug Conjugate Combination Clinical Trials
- Table 3-1: Breast Cancer - Approved Second Generation Antibody Drug Conjugates
- Table 3-2: Breast Cancer - Approved Third Generation Antibody Drug Conjugates
- Table 3-3: Fourth Generation Antibody Drug Conjugates - Examples
- Table 4-1: Breast Cancer - Approved Antibody Drug Conjugates, September'2025
- Table 5-1: Breast Cancer - Approved Antibody Drug Conjugates
- Table 6-1: US - Approved Breast Cancer Antibody Drug Conjugates, September'2025
- Table 6-2: China - Approved Antibody Drug Conjugates, September'2025
- Table 6-3: EU - Approved Cancer Antibody Drug Conjugates, September'2025
- Table 6-4: Australia - Approved Cancer Antibody Drug Conjugates, September'2025
- Table 6-5: Canada - Approved Cancer Antibody Drug Conjugates, September'2025
- Table 6-6: Japan - Approved Cancer Antibody Drug Conjugates, September'2025
- Table 6-7: UK - Approved Antibody Drug Conjugates, September'2025
- Table 7-1: Datroway - Premedication & Concomitant Medications
- Table 7-2: Datroway - Recommended Dosage Reductions for Adverse Reactions
